Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), today announced that it has changed its name to AIM ImmunoTech Inc. effective September 3, 2019. Additionally, the Company announced that effective September 3, 2019, the Company’s ticker will change to “AIM.” The Company’s common stock will continue to trade on the NYSE American.

Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovarian cancer in its Phase 1 trial using Ampligen with Intron A and celecoxib. The research team, led by Drs. Robert Edwards, Anda Vlad and Brian Orr, found that Ampligen was well tolerated on an intraperitoneal basis and as a combination therapy. “This concludes that these drugs can be given in this combination with no major toxicities noted and no evidence of added toxicity when adding the immunomodulators to cisplatin as most of the grade 3 toxicities listed above are common with cisplatin,” wrote Dr. Orr in the Phase 1 report.

Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today announced that its stockholders voted in favor to grant the Board of Directors the authority to effect a reverse stock split of the company’s issued and outstanding shares of Common Stock. The proposal passed by approximately 55% of all issued and outstanding shares and approximately 86% of the shares actually voted were voted in favor of the reverse split. Following the stockholder vote, the Board met and approved a 1-for-44 reverse stock split to achieve a value of approximately $5 per share.

OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) (See: https://clinicaltrials.gov/ct2/show/NCT03734692). On receipt of information from clinical sites, it is Hemispherx’ policy to provide periodic updates when a clinical study (1) is FDA authorized, (2) begins enrollment, (3) treats its first subject, (4) issues material interim reports and (5) releases final results. The company is pleased to announce this step in our clinical program, which constitutes steady progress toward Hemispherx’ clinical goals.

Companies in the news are: PLAY, NEPT, TGODF, RGS, GOOGL and HEB

Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the second quarter, which ended June 30, 2019, and provides a business update.

Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after nearly a quarter century with the company. Pascale joined Hemispherx in 1995 as an accounting manager, rising to the position of Chief Accounting Officer before being named CFO in 2016. Pascale has been an integral part of Hemispherx’s leadership team since being named CFO, helping to execute CEO Thomas K. Equels’ long-term business plan to test the company’s lead product Ampligen in the treatment of cancer.

Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of existing cancer immunotherapies, such as checkpoint blockade therapies. The company has five ongoing immuno-oncology clinical trials, four planned clinical trials and an active Early Access Program (EAP). The most recent addition to the ongoing group is a clinical study in the treatment of prostate cancer, where FDA authorization has been received.

Thomas Equels has been the CEO of Hemispherx Biopharma, Inc. (NYSEMKT:HEB) since 2016. First, this article will...

LOS ANGELES, CA / ACCESSWIRE / July 2, 2019 / StockNewsNow.com , The Official MicroCap News Source ™ , today published an SNNLive Video Interview with Thomas Equels, CEO of Hemispherx Biopharma, Inc. (NYSE ...

Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI algorithms following the filing of an 8-K on July 22, 2019. The two stock news organizations, Sagient Research and StreetAccount, both misreported that the company was raising $70 million in an Equity Distribution Agreement when, actually, the company was simply renewing a prior EDA that was related to an ATM and making the requisite SEC filings to raise up to $4.5 million under the new EDA, the maximum permitted at this time.

If you're interested in Hemispherx Biopharma, Inc. (NYSEMKT:HEB), then you might want to consider its beta (a measure...

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...